- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05885828
Estudo PRECISION-T2D: Estudo de nutrição de precisão para diabetes tipo 2
Food plays a crucial role in determining blood glucose levels, especially in people with type 2 diabetes. Precision nutrition, which involves individually tailored dietary interventions, can be a powerful tool in managing blood glucose levels in people with type 2 diabetes. Previous studies found that changes in gut microbiota resulted from the dietary intervention, such as plant-based diet, might subsequently lead to different glycemic responses, and then different health outcomes.
In this study, the investigators will characterize the blood glucose dynamics and gut microbiota of individuals with type 2 diabetes. They aim to assess the influence of plant-based diet on gut microbiota; they will also investigate the influence of gut microbiota on glycemic responses. Additionally, a series of individual N-of-1 trails will be integrated to compare the effects of a white bread breakfast and a whole wheat bread breakfast on glucose metabolism at the individual level.
Visão geral do estudo
Status
Condições
Descrição detalhada
Choice of design: The study is a two-arm intervention study integrated with N-of-1 design.
Study population: Patients with type 2 diabetes.
Screening Assessment: Prospective participants will be selected based on the pre-defined inclusion and exclusion criteria. Recruitment will be done over the phone and via the social media.
Study duration: Each participant will take part in the study for a period of up to 1 month at baseline and have follow-up visits every 1-2 years.
Dietary intervention:
The PRECISION-T2D is a dietary intervention study. Upon admission, patients will be randomly assigned to two groups: plant-based diet and conventional diabetic diet. Throughout the hospitalization, all participants (n=200) will be given standardized meals. A dietitian will design the diet for both plant-based and conventional diabetic diet groups following 2023 Chinese Diabetes Society guidelines. Both diets comprised approximately 50-65% of energy from carbohydrates, 20-30% of energy from fat, 15-20% from protein. The plant-based diet had higher fiber content (25-30g) compared to the conventional diabetic diet (15-20g). Participants will be asked to consume the entire amount of food indicated for the standardized meals and to record any leftover food. All participants will be asked to track their meals, snacks and drinks with instructions on how to record their daily dietary information. Participants will also be advised not to modify their exercise habits during the course of the study. Upon discharge, Participants in the plant-based diet arm will be recommended to consume more fiber-rich foods, including whole grains, fruits, legumes and vegetables; to moderate their intake of fish, eggs and dairy products; and to avoid other animal products. Participants in the conventional diabetic diet arm will be recommended to have a diet following 2023 Chinese Diabetes Society guidelines. Individual N-of-1 trial design will be employed to all participants during day one to day twelve to compare the difference of postprandial glucose response to white bread or whole wheat bread. These two standard breakfasts will appear in pseudo-random order. During the participants' first baseline visit day, they will be asked to complete a baseline questionnaire to collect information on their lifestyle, dietary habits, history of medications, sleep quality and appetite. Anthropometric measurements, ultrasonography evaluation, and laboratory tests will be taken using standard protocols. Participants will then be asked to wear a continuous glucose monitor (CGM) for 14-day blood glucose monitoring, which will be done by a nurse. On day 14, participants will be asked to come in for a clinical visit where they will receive their CGM report and provide blood, saliva, urine and stool samples. On day 30, participants will be asked to come in for another clinical visit where they will provide blood, saliva, urine and stool samples.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310058
- Hangzhou Third People's Hospital
-
Hangzhou, Zhejiang, China, 310030
- Westlake University
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Diagnosed with type 2 diabetes;
- Living in Hangzhou for at least five years;
- Have the willingness or ability to complete the intervention and sample collection
Exclusion Criteria:
- Mental and physical disability;
- Already is a vegetarian;
- Cancer and serious complications from type 2 diabetes, such as renal failure;
- Using insulin for more than 5 years;
- Unstable medical/medication status;
- Current alcohol or drug abuse;
- Taking antibiotics in the last three months
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Plant-based diet
Participants in this arm will be recommended to consume more fiber-rich foods, including whole grains, fruits, legumes and vegetables; to moderate their intake of fish, eggs and dairy products; and to avoid other animal products. All participants are instructed not to modify their exercise habits during the intervention period. |
After wearing CGM on Day 1, participants will be provided with white bread (76-77g) and milk (250mL) for breakfast on Day 3, Day 4, Day 7, Day 8, Day 10, Day 12.
Outros nomes:
After wearing CGM on Day 1, participants will be provided with wheat bread (85-86g) and milk (250mL) for breakfast on Day 2, Day 5, Day 6, Day 9, Day 11, Day 13.
Outros nomes:
After wearing CGM on Day 1, participants will be asked to follow the plant-based diet in next 30 days. Participants will be visited every 1-2 years. At each visit, face-to-face interviews, specimen collection, anthropometric measurements, ultrasonography evaluation, laboratory tests, and multi-omics data will be conducted. |
|
Experimental: Conventional diabetic diet
Participants in this arm will be recommended to have a diet following 2023 Chinese Diabetes Society guidelines. All participants are instructed not to modify their exercise habits during the intervention period. |
After wearing CGM on Day 1, participants will be provided with white bread (76-77g) and milk (250mL) for breakfast on Day 3, Day 4, Day 7, Day 8, Day 10, Day 12.
Outros nomes:
After wearing CGM on Day 1, participants will be provided with wheat bread (85-86g) and milk (250mL) for breakfast on Day 2, Day 5, Day 6, Day 9, Day 11, Day 13.
Outros nomes:
Participants will be visited every 1-2 years. At each visit, face-to-face interviews, specimen collection, anthropometric measurements, ultrasonography evaluation, laboratory tests, and multi-omics data will be conducted. Volunteers will be asked to have a diet following 2023 Chinese Diabetes Society guidelines in next 30 days. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Continuous glucose monitoring-derived mean blood glucose
Prazo: 2 weeks
|
Real-time glucose profiles will be recorded using continuous glucose monitoring. Average of all glucose measurements during the up to 14 days CGM wear will be calculated in mmol/L. |
2 weeks
|
|
Continuous glucose monitoring-derived time-in-range
Prazo: 2 weeks
|
Real-time glucose profiles will be recorded using continuous glucose monitoring. Percentage of glucose measurements that wear in the range of 3.9-10.0 mmol/L during the up to 14 days CGM will be calculated. |
2 weeks
|
|
Continuous glucose monitoring-derived coefficient of variation
Prazo: two weeks
|
Continuous glucose monitoring-derived time-in-range Real-time glucose profiles will be recorded using continuous glucose monitoring. Coefficient of variation was defined as standard deviation divided by mean glucose and multiplied by 100, during the up to 14 days wear. |
two weeks
|
|
Changes in gut microbiome profile
Prazo: Day 1, 15 and 31
|
Shotgun metagenomic sequencing will be performed in stool samples. |
Day 1, 15 and 31
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Changes in fasting blood glucose
Prazo: Day 1, 15 and 31
|
Fasting glucose will be examined in mmol/L. |
Day 1, 15 and 31
|
|
Changes in fasting blood C-peptide
Prazo: Day 1, 15 and 31
|
Fasting blood C-peptide will be examined in μg/L. |
Day 1, 15 and 31
|
|
Changes in fasting blood HbA1c
Prazo: Day 1, 15 and 31
|
Fasting blood HbA1c will be examined in %. |
Day 1, 15 and 31
|
|
Changes in lipid metabolism
Prazo: Day 1, 15 and 31
|
Triglyceride, cholesterol, high density lipoprotein cholesterol and low density lipoprotein cholesterol will be examined in mmol/L. |
Day 1, 15 and 31
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Ju-Sheng Zheng, PhD, Westlake University
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças do Sistema Endócrino
- Doenças Metabólicas
- Distúrbios do Metabolismo da Glicose
- Diabetes Mellitus
- Doenças Nutricionais e Metabólicas
- Diabetes Mellitus, Tipo 2
- Terapêutica
- Dieta, comida e nutrição
- Fenômenos fisiológicos
- Fenômenos fisiológicos nutricionais
- Dieta terapia
- Terapia nutricional
- Dieta
- Dieta, baseada em plantas
Outros números de identificação do estudo
- 20230306ZJS002
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .